Data Analysis of Adult and Pediatric Participants With Acid Sphingomyelinase Deficiency (ASMD) on Early Access to Olipudase Alfa in France

Study Overview

Primary Objective:
To describe the lung, spleen and liver outcomes of olipudase alfa
Secondary Objectives:
  • To describe the patient's characteristics
  • To describe conditions of olipudase alfa use
  • To describe safety data related to the use of olipudase alfa
  • To describe complementary effectiveness outcomes parameters

Study details

Approximate duration of enrollment: 18 months
Total study duration: approximately 3 years
This is a national, multicenter observational retrospective and prospective cohort data collection study. Retrospective is defined as collection of data from all patients, including deceased patients, who were already on early access olipudase alfa in France before the start of this study.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acid Sphingomyelinase Deficiency (ASMD)
  • Gender: All

Inclusion Criteria:
  • The patient, or the patient's parent(s)/guardian(s), has signed written informed consent.
  • Patients with a confirmed diagnosis of ASMD under early access to olipudase alfa in France (ie, nominative compassionate use, pre marketing authorization early access, post marketing authorization early access).
  • The patient has documented deficiency of acid sphingomyelinase in peripheral leukocytes, lymphocytes, or cultured fibroblasts.
  • Male and female patients of all ages.
Exclusion Criteria:
  • The patient or legal guardian(s) who has not received information notice or who opposes to data collection.
  • Patient who died before study initiation and who was opposed to data collection for research purpose when he/she was alive.
        The above information is not intended to contain all considerations relevant to a potential
        participation in a clinical trial.

Updated on 27 Mar 2024. Study ID: NCT05359276

Find a Study Location to Connect

What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site